Overview
Metastatic malignant neoplasms involving the diaphragm present a complex clinical challenge, often leading to significant symptom burden, particularly dyspnea and pain. These metastases can significantly impact a patient's quality of life and functional status. Effective management requires a multidisciplinary approach, integrating palliative care principles, symptom control, and patient-centered decision-making. Understanding the clinical presentation, diagnostic approaches, and tailored management strategies is crucial for optimizing outcomes and enhancing patient comfort. This guideline synthesizes evidence to guide clinicians in addressing the multifaceted needs of patients with metastatic disease affecting the diaphragm.
Clinical Presentation
Patients with metastatic malignant neoplasms involving the diaphragm often present with a constellation of symptoms, with dyspnea being a predominant complaint. Clinical observations indicate that higher heart rates are associated with greater refractoriness to palliative interventions, suggesting that patients with elevated heart rates may require more intensive or alternative management strategies [PMID:32088356]. This relationship underscores the importance of monitoring heart rate as a potential prognostic and therapeutic indicator. Additionally, the intensity of dyspnea at initial presentation plays a critical role in treatment outcomes. Patients experiencing higher baseline levels of dyspnea often face greater challenges in achieving their personalized dyspnea goals, as indicated by studies using the Edmonton Symptom Assessment Score (ESAS) [PMID:30336213]. Achieving these goals, however, is associated with improved global impressions of improvement, highlighting the value of setting and striving for individualized symptom targets. Lower initial dyspnea intensity and higher Karnofsky performance scores are predictive factors for successfully meeting these goals, emphasizing the need for early and aggressive symptom management.
Diagnosis
Accurate diagnosis of metastatic disease involving the diaphragm is essential for effective management. Recent advancements in imaging techniques have streamlined diagnostic processes. Diagnostic computed tomography (dCT) scans, performed within 28 days and in reproducible patient positions, have demonstrated comparable efficacy to traditional CT simulation scans for planning palliative radiation therapy [PMID:38613562]. This approach not only ensures adequate target coverage but also significantly reduces the time in center (TIC), from approximately 4.7 ± 1.1 hours to 0.41 ± 0.14 hours, thereby enhancing patient convenience and satisfaction. Clinicians should consider leveraging dCT scans to optimize treatment planning while minimizing patient burden. Furthermore, imaging should be complemented by thorough clinical assessments to fully characterize the extent of disease and its impact on respiratory function and overall health status.
Management
The management of metastatic malignant neoplasms to the diaphragm focuses on symptom control, functional improvement, and patient-centered care. Palliative radiation therapy remains a cornerstone, with studies showing that using diagnostic CT scans (dCT) for planning can substantially reduce patient time in the hospital setting without compromising treatment efficacy [PMID:38613562]. This efficiency not only improves patient acceptability but also allows for more frequent and timely interventions. Pharmacologically, opioids are the mainstay for managing breathlessness, given their efficacy in advanced cancer patients [PMID:20151348]. However, non-pharmacological interventions such as walking aids and neuromuscular electrical stimulation, though primarily studied in chronic obstructive pulmonary disease (COPD) populations, may offer supplementary benefits in this context [PMID:20151348]. It is crucial to tailor these interventions based on individual patient needs and preferences.
Shared decision-making (SDM) and goal-concordant care are increasingly recognized as vital components in managing these patients [PMID:36154697]. Surgeons trained in HPM (Hospice and Palliative Medicine) methodologies report enhanced abilities to apply SDM principles, reducing personal biases and fostering more balanced treatment approaches [PMID:36154697]. This approach ensures that treatment plans align closely with patients' values and goals, particularly important in palliative settings. Additionally, initiating discussions about end-of-life care early, facilitated through tools like MOLST (Medical Orders for Life-Sustaining Treatment) forms, has been shown to be both feasible and beneficial in oncology settings [PMID:26800409]. These discussions empower patients and families, aligning care with patient wishes and improving overall satisfaction.
Comprehensive inpatient rehabilitation programs can also yield significant benefits, particularly for elderly patients experiencing asthenia, by enhancing both physical and mental function [PMID:10829146]. Such programs may help mitigate caregiver burden and optimize resource allocation in long-term care settings. However, it is important to note that interventions like benzodiazepines, anxiolytics, antidepressants, phenothiazines, inhaled furosemide, and supplemental oxygen lack robust evidence for routine use in managing breathlessness in advanced cancer patients [PMID:20151348]. Clinicians should exercise caution and consider these options only when other evidence-based treatments are insufficient or contraindicated.
Complications
Despite comprehensive palliative care efforts, managing complications remains challenging. Studies indicate that a notable proportion of patients—approximately 21.5%—experience no change in dyspnea intensity, and a smaller percentage (4.7%) may even experience worsening symptoms [PMID:30336213]. These findings underscore the necessity for individualized approaches, recognizing that each patient's response to treatment can vary significantly. Tailoring interventions based on initial symptom severity, functional status, and patient-specific factors is crucial to mitigate these complications effectively. Regular reassessment and flexible adjustment of treatment plans are essential to address evolving symptomatology and maintain quality of life.
Prognosis & Follow-up
Prognostic indicators in patients with metastatic malignant neoplasms to the diaphragm include heart rate and symptom response. Lower heart rates (≤74 bpm) are associated with longer survival periods, with median survival times extending to 24 days compared to significantly shorter durations (9 days) in patients with higher heart rates (≥98 bpm) [PMID:32088356]. Monitoring heart rate alongside symptom improvement, particularly in dyspnea intensity and delirium, provides valuable insights into prognosis and treatment efficacy [PMID:30336213]. Improvements in these areas are strongly correlated with better global impressions of patient well-being, emphasizing the importance of regular follow-up assessments. Functional gains achieved through rehabilitation can also influence care planning, potentially reducing the burden on caregivers and optimizing resource utilization in long-term care scenarios [PMID:10829146].
Special Populations
Special attention is warranted for specific patient subgroups, including healthcare providers themselves. The well-being of surgeons and other clinicians managing these complex cases is crucial for sustaining high-quality care [PMID:36154697]. Programs aimed at enhancing wellness and resilience among healthcare providers can mitigate burnout and ensure sustained competence in delivering compassionate, evidence-based care. Additionally, geriatric considerations are paramount given the often advanced age of patients with metastatic disease, necessitating geriatric assessments and tailored interventions to address age-related comorbidities and functional decline.
Key Recommendations
References
1 O'Neil M, Laba JM, Nguyen TK, Lock M, Goodman CD, Huynh E et al.. Diagnostic CT-Enabled Planning (DART): Results of a Randomized Trial in Palliative Radiation Therapy. International journal of radiation oncology, biology, physics 2024. link 2 Bassette E, Salyer C, McCammon S, Veazey Brooks J, Spoozak L. Value of Hospice and Palliative Medicine Fellowship After Surgical Training: Bridging the Gap for Improved Patient Care. The American journal of hospice & palliative care 2023. link 3 Mori I, Maeda I, Morita T, Inoue S, Ikenaga M, Sekine R et al.. Association Between Heart Rate and Reversibility of the Symptom, Refractoriness to Palliative Treatment, and Survival in Dyspneic Cancer Patients. Journal of pain and symptom management 2020. link 4 Mercadante S, Adile C, Aielli F, Lanzetta G, Mistakidou K, Maltoni M et al.. Personalized Goal for Dyspnea and Clinical Response in Advanced Cancer Patients. Journal of pain and symptom management 2019. link 5 Evans JN, Ball LS, Wicher CP. Implementation of Medical Orders for Life-Sustaining Treatment. Clinical journal of oncology nursing 2016. link 6 Simon ST, Bausewein C. Management of refractory breathlessness in patients with advanced cancer. Wiener medizinische Wochenschrift (1946) 2009. link 7 Scialla S, Cole R, Scialla T, Bednarz L, Scheerer J. Rehabilitation for elderly patients with cancer asthenia: making a transition to palliative care. Palliative medicine 2000. link
7 papers cited of 8 indexed.